Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Expands By 859.7%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,430,000 shares, a growth of 859.7% from the March 31st total of 149,000 shares. Based on an average trading volume of 632,000 shares, the short-interest ratio is currently 2.3 days.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CLDI shares. Robert W. Baird dropped their price objective on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating on the stock in a report on Thursday, March 21st. HC Wainwright dropped their price objective on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, March 21st.

Calidi Biotherapeutics Stock Performance

CLDI stock opened at $0.16 on Friday. Calidi Biotherapeutics has a 52-week low of $0.14 and a 52-week high of $13.79.

Institutional Investors Weigh In On Calidi Biotherapeutics

A hedge fund recently bought a new stake in Calidi Biotherapeutics stock. Spectrum Asset Management Inc. NB CA bought a new stake in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 166,494 shares of the company’s stock, valued at approximately $94,000. Spectrum Asset Management Inc. NB CA owned 0.47% of Calidi Biotherapeutics as of its most recent SEC filing. 12.53% of the stock is currently owned by hedge funds and other institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.